Mesabi Trust (MSB - Get Report) has been named as a Top 5 dividend paying metals and mining stock, according to Dividend Channel, which published its weekly ''DividendRank'' report. The report noted that among metals and mining companies, MSB shares displayed both attractive valuation metrics and strong profitability metrics. The report also cited the strong quarterly dividend history at Mesabi Trust, and favorable long-term multi-year growth rates in key fundamental data points.The report stated, '' Dividend investors approaching investing from a value standpoint are generally most interested in researching the strongest most profitable companies, that also happen to be trading at an attractive valuation. That's what we aim to find using our proprietary DividendRank formula, which ranks the coverage universe based upon our various criteria for both profitability and valuation, to generate a list of the top most 'interesting' stocks, meant for investors as a source of ideas that merit further research.'' The annualized dividend paid by Mesabi Trust is $0.64/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/26/2017. Below is a long-term dividend history chart for MSB, which Dividend Channel stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.
More from Stocks
The Charts of Zendesk Could Use Some Meditation and Stress Management
Where are we headed next?
The Impressive Rally in HubSpot Is Likely to Continue to the $250 Area
Let's check out the charts.
Dow Rises After Yield Curve Returns to Normal Though Recession Fears Remain
Stocks are mixed as bond yields invert - a possible recession warning - and then normalize ahead of Fed Chairman Jerome Powell's scheduled address Friday at the annual Jackson Hole Economic Symposium.
GameStop Spikes After Investor Michael Burry Goes Long on Video Game Retailer
Michael Burry is famous for being one of the first investors to short subprime mortgages before the financial crisis, and was depicted by Christian Bale in the movie "The Big Short."
Retrophin Tanks After Neurological Treatment Fails Late-Stage Study
The treatment, fosmetpantotenate, fails to meet its primary endpoint when compared to a control group being treated with a placebo, the company says.